Tenax Therapeutics ( (TENX) ) has released its Q3 earnings. Here is a breakdown of the information Tenax Therapeutics presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tenax Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing novel cardiopulmonary therapies, leveraging clinical insights to target disease pathophysiology. The company is actively conducting clinical trials for levosimendan and imatinib, drugs with potential to improve the lives of patients with pulmonary hypertension.
In its latest earnings report for the quarter ended September 30, 2025, Tenax Therapeutics highlighted a significant increase in operating expenses, primarily driven by research and development activities. The company reported a net loss of $15.8 million for the quarter, reflecting its ongoing investment in clinical trials and product development.
Key financial metrics showed a substantial increase in research and development expenses, which rose by 232% compared to the same period last year, reaching $10.3 million. General and administrative expenses also saw a significant rise, increasing by 330% to $6.5 million. Despite these expenses, the company maintained a strong cash position with $99.4 million in cash and cash equivalents.
Looking ahead, Tenax Therapeutics plans to continue advancing its Phase 3 clinical trials for levosimendan and imatinib, with the goal of submitting marketing authorization applications upon successful completion. The company believes it has sufficient resources to continue operations through 2027, as it seeks to deliver breakthrough therapies for pulmonary hypertension.